Is Voyager Therapeutics Stock a Good Investment?
Voyager Therapeutics Investment Advice | VYGR |
- Examine Voyager Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Voyager Therapeutics' leadership team and their track record. Good management can help Voyager Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Voyager Therapeutics' business and its evolving consumer preferences.
- Compare Voyager Therapeutics' performance and market position to its competitors. Analyze how Voyager Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Voyager Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Voyager Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Voyager Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Voyager Therapeutics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Moderately volatile | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Voyager Therapeutics Stock
Researching Voyager Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 17.0% of the company outstanding shares are owned by insiders. The company has Price to Book (P/B) ratio of 0.95. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Voyager Therapeutics had not issued any dividends in recent years.
To determine if Voyager Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Voyager Therapeutics' research are outlined below:
Voyager Therapeutics had very high historical volatility over the last 90 days | |
About 66.0% of the company outstanding shares are owned by institutional investors | |
Latest headline from news.google.com: Voyager Therapeutics, Inc. Receives 17.00 Consensus PT from Brokerages - MarketBeat |
Voyager Therapeutics Quarterly Cost Of Revenue |
|
Voyager Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Voyager Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Voyager Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
5th of March 2024 Upcoming Quarterly Report | View | |
14th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
5th of March 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Voyager Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Voyager Therapeutics' investors have experienced.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2023-08-03 | 2023-06-30 | -0.57 | -0.51 | 0.06 | 10 | ||
2023-03-07 | 2022-12-31 | -0.55 | -0.61 | -0.06 | 10 | ||
2016-11-10 | 2016-09-30 | -0.41 | -0.35 | 0.06 | 14 | ||
2021-05-10 | 2021-03-31 | -0.66 | -0.58 | 0.08 | 12 | ||
2021-08-09 | 2021-06-30 | -0.71 | -0.8 | -0.09 | 12 | ||
2016-05-12 | 2016-03-31 | -0.38 | -0.29 | 0.09 | 23 | ||
2017-03-15 | 2016-12-31 | -0.46 | -0.57 | -0.11 | 23 | ||
2017-08-08 | 2017-06-30 | -0.61 | -0.73 | -0.12 | 19 |
Know Voyager Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Voyager Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Voyager Therapeutics backward and forwards among themselves. Voyager Therapeutics' institutional investor refers to the entity that pools money to purchase Voyager Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Federated Hermes Inc | 2024-09-30 | 551.4 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 540.7 K | Bank Of America Corp | 2024-09-30 | 531.6 K | Vestal Point Capital Lp | 2024-09-30 | 490 K | Prudential Financial Inc | 2024-09-30 | 412.4 K | Northern Trust Corp | 2024-09-30 | 406.4 K | Goldman Sachs Group Inc | 2024-09-30 | 328.3 K | Globeflex Capital, L.p. | 2024-09-30 | 291.3 K | Renaissance Technologies Corp | 2024-09-30 | 278.7 K | Blackrock Inc | 2024-06-30 | 5.3 M | Armistice Capital, Llc | 2024-09-30 | 5.2 M |
Voyager Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 314.1 M.Voyager Therapeutics' profitablity analysis
The company has Profit Margin (PM) of 0.16 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of (0.56) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.56.Determining Voyager Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Voyager Therapeutics is a good buy. For example, gross profit margin measures Voyager Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Voyager Therapeutics' profitability and make more informed investment decisions.
Evaluate Voyager Therapeutics' management efficiency
Voyager Therapeutics has return on total asset (ROA) of 0.0157 % which means that it generated a profit of $0.0157 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1022 %, meaning that it created $0.1022 on every $100 dollars invested by stockholders. Voyager Therapeutics' management efficiency ratios could be used to measure how well Voyager Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.At Voyager Therapeutics, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Beta 0.889 |
Basic technical analysis of Voyager Stock
As of the 23rd of December, Voyager Therapeutics has the Semi Deviation of 4.92, risk adjusted performance of 0.0096, and Coefficient Of Variation of 81032.38. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Voyager Therapeutics, as well as the relationship between them. Please validate Voyager Therapeutics market risk adjusted performance, variance, as well as the relationship between the Variance and potential upside to decide if Voyager Therapeutics is priced more or less accurately, providing market reflects its prevalent price of 5.75 per share. Given that Voyager Therapeutics has jensen alpha of (0.07), we advise you to double-check Voyager Therapeutics's current market performance to make sure the company can sustain itself at a future point.Voyager Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Voyager Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Voyager Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Voyager Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Voyager Therapeutics' Outstanding Corporate Bonds
Voyager Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Voyager Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Voyager bonds can be classified according to their maturity, which is the date when Voyager Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Dana 575 percent Corp BondUS235822AB96 | View | |
Volcan Compania Minera Corp BondUSP98047AC08 | View | |
Boeing Co 2196 Corp BondUS097023DG73 | View | |
MPLX LP 4875 Corp BondUS55336VAG59 | View | |
MPLX LP 4125 Corp BondUS55336VAK61 | View | |
MPLX LP 52 Corp BondUS55336VAL45 | View | |
VMC 715 30 NOV 37 Corp BondUS929160AG40 | View | |
VULCAN MATLS 45 Corp BondUS929160AV17 | View |
Understand Voyager Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Voyager Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
Risk Adjusted Performance | 0.0096 | |||
Market Risk Adjusted Performance | 0.009 | |||
Mean Deviation | 3.62 | |||
Semi Deviation | 4.92 | |||
Downside Deviation | 5.23 | |||
Coefficient Of Variation | 81032.38 | |||
Standard Deviation | 5.56 | |||
Variance | 30.87 | |||
Information Ratio | (0) | |||
Jensen Alpha | (0.07) | |||
Total Risk Alpha | (0.16) | |||
Sortino Ratio | (0) | |||
Treynor Ratio | (0) | |||
Maximum Drawdown | 36.72 | |||
Value At Risk | (7.03) | |||
Potential Upside | 9.47 | |||
Downside Variance | 27.39 | |||
Semi Variance | 24.25 | |||
Expected Short fall | (3.99) | |||
Skewness | 0.6542 | |||
Kurtosis | 4.62 |
Risk Adjusted Performance | 0.0096 | |||
Market Risk Adjusted Performance | 0.009 | |||
Mean Deviation | 3.62 | |||
Semi Deviation | 4.92 | |||
Downside Deviation | 5.23 | |||
Coefficient Of Variation | 81032.38 | |||
Standard Deviation | 5.56 | |||
Variance | 30.87 | |||
Information Ratio | (0) | |||
Jensen Alpha | (0.07) | |||
Total Risk Alpha | (0.16) | |||
Sortino Ratio | (0) | |||
Treynor Ratio | (0) | |||
Maximum Drawdown | 36.72 | |||
Value At Risk | (7.03) | |||
Potential Upside | 9.47 | |||
Downside Variance | 27.39 | |||
Semi Variance | 24.25 | |||
Expected Short fall | (3.99) | |||
Skewness | 0.6542 | |||
Kurtosis | 4.62 |
Consider Voyager Therapeutics' intraday indicators
Voyager Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Voyager Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Voyager Therapeutics Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 12th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 3rd of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 9th of July 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Voyager Stock media impact
Far too much social signal, news, headlines, and media speculation about Voyager Therapeutics that are available to investors today. That information is available publicly through Voyager media outlets and privately through word of mouth or via Voyager internal channels. However, regardless of the origin, that massive amount of Voyager data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Voyager Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Voyager Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Voyager Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Voyager Therapeutics alpha.
Voyager Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Voyager Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Voyager Therapeutics Corporate Management
Sandrock MD | CEO Pres | Profile | |
Dr MBA | Chief Officer | Profile | |
JD Esq | Chief Officer | Profile | |
Todd Carter | Chief Officer | Profile |
Additional Tools for Voyager Stock Analysis
When running Voyager Therapeutics' price analysis, check to measure Voyager Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Voyager Therapeutics is operating at the current time. Most of Voyager Therapeutics' value examination focuses on studying past and present price action to predict the probability of Voyager Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Voyager Therapeutics' price. Additionally, you may evaluate how the addition of Voyager Therapeutics to your portfolios can decrease your overall portfolio volatility.